📅 PUBMED DAILY TRIAGE — 2026-06-10
Window: 2026-06-09T09:00:00Z → 2026-06-10T09:00:00Z (CRDT)
Topics scanned: 10 (9 watchlist + 1 sentinel) | Candidates evaluated: ~98 | Articles classified: 20
High priority: 2 | Standard: 16 | Low/archive: 2 | Unsolicited finds: 0
Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Early Cancer Detection (Liquid Biopsy / ctDNA)
TR-2026-06-10-001 · PMID 42262988 · The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration · 8/10 🔴
Mehta S et al. · Cancer (2026) · DOI: 10.1002/cncr.70448
→ First unified ctDNA integration framework across all UC stages (61 studies): stage-specific detection rates, adjuvant therapy guidance in MIBC (ctDNA+ = HR 6.3 worse OS), treatment monitoring in mUC; 94-100% recurrence detection sensitivity with 96-131 day lead time.
TR-2026-06-10-002 · PMID 42261877 · Bile-Derived Exosomal miR-196a/-196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer · 8/10 🔴
Kugiyama N et al. · Cancer Science (2026) · DOI: 10.1111/cas.70443
→ Novel bile liquid biopsy for biliary tract cancer: miR-196a AUROC 0.79 alone, rising to 0.88 combined with CA19-9+CEA; miR-196a detects early-stage BTC; multi-cohort validation (n=203 total). Critical unmet need — BTC typically presents late.
Other topics with zero 8+ articles today:
- Hematologic malignancies: best 6/10 (PMID 42263372, MM elderly NCDB)
- CBC/ML diagnostics: best 0/10 — no qualifying articles (sixth consecutive day)
- AI/ML diagnostics: best 6/10 (PMID 42263377, ML CRC emergency resection)
- Precision oncology: best 7/10 (PMID 42263332, HER2 NSCLC real-world)
- Novel therapeutics: best 7/10 (PMID 42262537, LDIL-2 for irAE)
- Cardiovascular-metabolic: best 6/10 (PMID 42263346, HBCR HF readmission)
- Aging/longevity: 0 results (humans[MeSH] filter returned nothing)
- Rare diseases: best 6/10 (PMID 42263369, UMAP myopathy MRI)
🟢⚪ STANDARD (5-7) — Top by Topic
Hematologic Malignancies
- TR-2026-06-10-012 · PMID 42263372 · Patterns of care for older MM patients, NCDB · 6/10 · Treatment Innovation
C+H+I combination yields 64.2 month median OS in MM ≥70 (HR=0.575) but is underutilized; NCDB 2004-2021 analysis.
Early Cancer Detection / Liquid Biopsy
- TR-2026-06-10-005 · PMID 42261901 · KIM-1 and beyond: emerging biomarkers for adjuvant immunotherapy in ccRCC · 6/10 · Genomics/Precision Medicine
Review: KIM-1 as liquid biomarker for adjuvant immunotherapy enrichment in resected ccRCC; integrative model including ctDNA and genomic drivers proposed. - TR-2026-06-10-015 · PMID 42262196 · Lenvatinib + atezolizumab in liver transplant recipients with HCC recurrence (n=15) · 5/10 · Treatment Innovation
Median OS 36 months, ORR 60%, no severe rejection in a high-unmet-need excluded population; ctDNA tracked imaging response.
AI/ML in Diagnostics and Imaging
- TR-2026-06-10-010 · PMID 42263377 · Age-stratified ML risk profiles for emergency CRC resection, n=510,135 · 6/10 · Public Health
CART identifies insurance status as dominant risk driver <75 years; clinical complexity dominant ≥76 years. Health equity implications. - TR-2026-06-10-011 · PMID 42263369 · UMAP dimensionality reduction for muscle MRI in genetic myopathies, n=975, multicenter · 6/10 · Diagnostics
UMAP achieves 87% top-3 diagnostic accuracy across 10 myopathy subtypes with GMM; practical rare disease diagnostic tool. - TR-2026-06-10-016 · PMID 42263351 · FeatStainDiff: diffusion-based H&E-to-IHC feature transformation for WSI analysis · 5/10 · Diagnostics
Feature-level (not pixel-level) virtual staining; potential to expand IHC access in resource-limited settings. - TR-2026-06-10-018 · PMID 42263371 · H2C self-tuned healthy core for biomedical ML classification · 4/10 · Diagnostics
Kernel density-based healthy cohort curation consistently improves F1 on cardiac/arrhythmia/migraine classifiers.
Precision Oncology and Genomic Medicine
- TR-2026-06-10-003 · PMID 42263332 · HER2-mutant NSCLC real-world outcomes, Japan n=3012 (C-CAT database) · 7/10 · Genomics/Precision Medicine
Largest real-world second-line HER2-mutant NSCLC dataset to date; post-approval benchmark for T-DXd and other HER2 agents. - TR-2026-06-10-006 · PMID 42263221 · Spatial transcriptomics identifies CEBPD/CXCL2 axis in HCC post-insufficient RFA · 6/10 · Drug Development
Visium HD reveals heat stress–CEBPD–CXCL2 immunosuppressive mechanism; CXCR2 inhibition as potential recurrence prevention strategy. - TR-2026-06-10-014 · PMID 42262875 · iSCST on FFPE UC biopsies: two VDZ resistance archetypes (JCI) · 6/10 · Diagnostics
Xenium on clinical FFPE identifies IAF-innate vs GALT-adaptive non-responder archetypes to vedolizumab; validated externally. - TR-2026-06-10-017 · PMID 42263382 · ET suitability framework for HR+ metastatic breast cancer (AstraZeneca-funded expert review) · 5/10 · Genomics/Precision Medicine
Framework concept useful; no new clinical data; all-author COI with AstraZeneca.
Novel Therapeutics
- TR-2026-06-10-004 · PMID 42262537 · Low-dose IL-2 for irAE management via Tfh/Treg balance, prospective n=26 · 7/10 · Treatment Innovation
First prospective characterization of Tfh/Treg ratio as irAE predictor; LDIL-2 restores balance in mouse models without impairing antitumor efficacy. - TR-2026-06-10-007 · PMID 42263195 · BiTE atrial fibrillation safety signal in FAERS (n=11.1M ICSRs) · 6/10 · Drug Development
Significant AF disproportionality for epcoritamab (ROR 2.95) and mosunetuzumab (ROR 3.88); clinical monitoring implications. - TR-2026-06-10-009 · PMID 42263355 · EADO/EDF/ESTRO/EORTC CSCC treatment guideline — update 2026 · 6/10 · Treatment Innovation
Cemiplimab confirmed as standard advanced CSCC therapy; adjuvant indication added; neoadjuvant concept formally addressed.
Cardiovascular-Metabolic
- TR-2026-06-10-008 · PMID 42263346 · Hemoglobin-creatinine ratio predicts 6-month HF readmission, n=1833 · 6/10 · Diagnostics
HBCR (zero-cost, routine labs) independently associated with 41% lower readmission risk in highest tertile; graded relationship. - TR-2026-06-10-013 · PMID 42263266 · Digital health interventions meta-analysis for chronic disease self-care (JMIR, SR of RCTs) · 6/10 · Public Health
Meta-analysis of RCTs shows digital health improves chronic disease self-care; relevant to HF and diabetes programs. Abstract truncated — full results pending.
💡 UNSOLICITED FINDS
None. All high-signal candidates from the sentinel scan were already captured by watchlist topics (primary: 42263372, 42263266, 42263354).
📊 TODAY'S BREAKDOWN
By research category:
- Diagnostics: 6 | Treatment Innovation: 5 | Genomics/Precision Medicine: 4 | Early Detection: 2 | Public Health: 3 | Drug Development: 2 | Other: 0
By evidence maturity:
- Validated: 10 | Exploratory: 8 | Potentially Practice-Changing: 0
By watchlist topic (reviewed / kept / highest score):
| Topic | Reviewed | Kept | Best Score |
|---|---|---|---|
| Hematologic malignancies | 10 | 3 | 6 |
| CBC/ML diagnostics | 7 | 0 | — |
| Liquid biopsy / ctDNA | 11 | 4 | 8 |
| AI/ML diagnostics | 10 | 4 | 6 |
| Precision oncology | 10 | 5 | 7 |
| Novel therapeutics | 10 | 5 | 7 |
| Cardiovascular-metabolic | 10 | 2 | 6 |
| Aging/longevity | 0 | 0 | — |
| Rare diseases | 10 | 1 | 6 |
| Sentinel scan | 10 | 0 | — |
By source type: Peer-reviewed: 20 | Preprint: 0
Topics with zero 8+ articles this run:
T1 (Hematologic), T2 (CBC/ML), T4 (AI/ML), T5 (Precision Oncology), T6 (Therapeutics), T7 (Cardiometabolic), T8 (Aging), T9 (Rare Diseases)
🔧 RUN NOTES
T2 CBC/ML — ESCALATION REQUIRED (Sixth Consecutive Day Zero):
Query was broadened per prior run note (added "peripheral blood smear", "automated differential", "flow cytometry"). Result: 7 records returned, but all were off-topic (flow cytometry immunology studies, nanoparticle toxicology, CLL case reports). The query is matching the right MeSH adjacencies but the literature window is not producing CBC-specific ML papers in this 24-hour period. Recommended query pivot for next run:("automated cell counting" OR "leukocyte differential" OR "morphology AI" OR "hematology analyzer") AND ("convolutional" OR "deep learning" OR "neural network" OR "classification algorithm") AND ("blood cells" OR "white blood cell" OR "red blood cell" OR "platelet")
T8 Aging/Longevity — Persistent MeSH Indexing Lag:
Zero results with humans[MeSH] for what appears to be the third occurrence in recent weeks. MeSH indexing of newly added records lags by days. Recommended fallback for next run: run query without humans[MeSH] but add AND (cohort OR trial OR clinical OR longitudinal OR intervention) as human context refiners instead.
T3 (Liquid Biopsy/ctDNA) continues strong signal:
Both HIGH articles today originated from T3 (PMID 42262988 — UC ctDNA SR, score 8; PMID 42261877 — bile miRNA BTC, score 8). This is consistent with the recent pattern: T3 has produced HIGH or near-HIGH articles in the majority of recent daily runs.
No window expansion triggered:
Total relevant records = 20 (>5), so no 48-hour expansion was needed.
Sentinel scan:
170 raw results; top 10 reviewed. All high-signal sentinel candidates were already captured by watchlist queries. No unique unsolicited finds.
T6 query note:
ADC abbreviation continues to match "Arch Dis Child" and "Acta Dermatovenerol Croat" journals; recommend replacing ADC with "antibody drug conjugate" (phrase-quoted, no hyphen) in next run.
Rolling 7-day topics with consistent zero high-priority articles:
CBC/ML (6 days), Aging/Longevity (≥3 days recently), Cardiovascular-metabolic (GLP-1/SGLT2 specific RCTs: absent for 3 days — broader cardiometabolic articles present but no primary drug trial data).